Results 21 to 30 of about 939 (187)

Ubrogepant Users' Real-World Experience: Patients on Ubrogepant, Characteristics and Outcomes (UNIVERSE) Study

Headache
Abstract Objective To assess the real‐world effectiveness of ubrogepant by evaluating self‐reported satisfaction with pain relief, ability to think clearly, and return to normal function in individuals who had used ubrogepant to treat a migraine episode within the preceding 14 days.
Ali Ezzati, Richard B. Lipton
exaly   +3 more sources

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system [PDF]

The Journal of Headache and Pain
Background Gepants have demonstrated notable benefits in migraine therapy, yet their safety profiles are not thoroughly investigated. This study comprehensively analyzed the adverse event (AE) risk signals of the currently approved gepants using the U.S.
Qi Song, Siyuan Gao, Yaqian Tan
doaj   +2 more sources

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine [PDF]

Drug Design, Development and Therapy
Mengyi Li, Siyong Huang, Jiabao Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Li M, Huang S, Li J, Hu X, Chen J
doaj   +2 more sources

Ubrogepant Does Not Induce Latent Sensitization in a Preclinical Model of Medication Overuse Headache

Cephalalgia, 2020
Background Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repeated oral ...
Frank Porreca, Edita Navratilova, Sasan Behravesh   +2 more
exaly   +4 more sources

Expert consensus on gepants for acute and preventive treatment of migraine in Thailand [PDF]

The Journal of Headache and Pain
Introduction Gepants, a calcitonin gene-related peptide (CGRP) receptor antagonist, is a class of migraine therapeutic options with extensive evidence supporting a favorable efficacy and safety profile. However, as a novel class of medication in Thailand,
Prakit Anukoolwittaya, Wanakorn Rattanawong, Kiratikorn Vongvaivanich, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Thaninjitra Poonpedpun, Pannathat Soontrapa, Kanokrat Suwanlaong, Kannikar Kongbunkiat, Surasak Komonchan, Petcharat Dusitanond, Chutithep Teekaput, Nopdanai Sirimaharaj, Nadolporn Yuvasilp, Surat Tanprawate   +14 more
doaj   +2 more sources

Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway [PDF]

The Journal of Headache and Pain, 2023
Background New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine specific medications (nAMSMs ...
Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs, Mark E. Bensink   +9 more
doaj   +2 more sources

Migrainous Thoracalgia in a Patient with Chronic Migraine and Coronary Vasospasm: A Case Report [PDF]

International Medical Case Reports Journal
Dean Zeldich,1 Victor S Wang,1,2 Cyril David,1 Clinton Lauritsen,1 Claire Ceriani1 1Department of Neurology, Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 2Department of Neurology, Sutter East Bay Medical Group ...
Zeldich D, Wang VS, David C, Lauritsen C, Ceriani C   +4 more
doaj   +2 more sources

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. [PDF]

Headache
Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Iannone LF, Silvestro M, Munafò A, Romozzi M, Geppetti P, Russo A.   +5 more
europepmc   +2 more sources

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases [PDF]

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li, Hailong Li, Hailong Li   +7 more
doaj   +2 more sources

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. [PDF]

Headache
Abstract Objective To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe. Background Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones
Ong B, Ahdab JE, Thompson N, Bhagat M, Ney J, Weathers AL.   +5 more
europepmc   +2 more sources